ImmuCell Corp (ICCC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.90-1.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ICCC
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Execute a multi-phase manufacturing capacity expansion program to triple First Defense production capacity by mid-2027.
Stated in 2 of last 2 quarters. Management detailed a $3.5 million freeze-drying capacity expansion expected to complete in the first half of 2027 and a planned $4.5 million investment in colostrum liquid processing capacity. These investments aim to triple First Defense production capacity by mid-2027. The trajectory is delivering as the company has secured funding and begun execution.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We previously announced an approximately $3.5 million investment in freeze-drying capacity that we expect to complete in the first half of 2027... In a second phase, we plan to invest approximately $…”
“We are planning a significant First Defense capacity expansion and recently settled disputes with our former contract manufacturer for $2 million to deploy toward this expansion.”
Drive year-over-year growth in product sales through market share gains and expanded commercial efforts.
Stated in 3 of last 3 quarters. Product sales grew from $8.1 million in 2025-Q1 to $10.4 million in 2026-Q1 (+28.4%) and from $6.45 million in 2025-Q2 to $7.2 million in 2026-Q2 (+11.5%). Full-year 2025 sales increased 4.3% to $27.6 million versus 2024. Management's focus on market share gains and commercial expansion is reflected in these sales increases, indicating delivery on this priority.
“Second quarter 2026 product sales increased 11.5% to $7.2 million compared to Q2 2025.”
“First quarter 2026 product sales increased 28.4% to $10.4 million compared to Q1 2025.”
“2025 product sales increased 4.3% to approximately $27.6 million compared to 2024.”
Address expected revenue moderation after peak seasonal demand and the impact of prior backorder clearance.
Stated in 2 of last 2 quarters. Management acknowledged mid-year revenue moderation post-peak season and the impact of a large backorder cleared in Q2 2025. Revenue declined 1.6% in Q4 2025 compared to Q4 2024, consistent with this seasonal moderation. The trajectory matches management's stated expectation of moderated growth after peak demand.
“As we move past our peak season, revenue traditionally moderates mid-year, and year over year growth rates will be impacted by the large backorder cleared in Q2 2025.”
“Total sales for the three-month period ended December 31, 2025 were $7.6 million, a 1.6% decline compared to the same period in 2024.”
Over the trailing year it converted 2.67x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 55% of the time over the next year (vs 45% for the rest of the cohort, n=2490).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
22 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.